तुलना करने के लिए मीट्रिक्स | PHVS | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधPHVSपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −11.2x | −7.2x | −0.2x | |
PEG अनुपात | −1.60 | 0.27 | 0.00 | |
क़ीमत/बुक | 7.7x | 4.4x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 61.9x | 2.7x | |
अपसाइड (विश्लेषक लक्ष्य) | 84.8% | 127.8% | 69.6% | |
उचित मूल्य अपसाइड | अनलॉक करें | −16.6% | 11.7% | अनलॉक करें |
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.